Somatostatin Receptor–PET/CT/MRI of Head and Neck Neuroendocrine Tumors

References

1. 1.↵
   2. Schimmack S,
   3. Svejda B,
   4. Lawrence B, et al

   . The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbecks Arch Surg 2011;396:273–98 doi:10.1007/s00423-011-0739-1 pmid:21274559

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Ivanidze J,
   3. Roytman M,
   4. Sasson A, et al

   . Molecular imaging and therapy of somatostatin receptor positive tumors. Clin Imaging 2019;56:146–54 doi:10.1016/j.clinimag.2019.04.006 pmid:31121520

   CrossRefPubMed
3. 3.↵
   2. Ivanidze J,
   3. Roytman M,
   4. Lin E, et al

   . Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging 2019;29:650–56 doi:10.1111/jon.12632 pmid:31107591

   CrossRefPubMed
4. 4.↵
   2. Janssen I,
   3. Chen CC,
   4. Taieb D, et al

   . 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med 2016;57:186–91 doi:10.2967/jnumed.115.161018 pmid:26564322

   Abstract/FREE Full Text
5. 5.↵
   2. Roytman M,
   3. Tassler AB,
   4. Kacker A, et al

   . [68Ga]-DOTATATE PET/CT and PET/MRI in the diagnosis and management of esthesioneuroblastoma: illustrative cases. J Neurosurg Case Lessons 2021;1:CASE2058 doi:10.3171/CASE2058 pmid:35854930

   CrossRefPubMed
6. 6.↵
   2. Boertien TM,
   3. Booij J,
   4. Majoie CB, et al

   . 68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. Eur J Hybrid Imaging 2020;4:4 doi:10.1186/s41824-020-0073-3 pmid:34191241

   CrossRefPubMed
7. 7.↵
   2. Garmes HM,
   3. Carvalheira JB,
   4. Reis F, et al

   . Pituitary carcinoma: a case report and discussion of potential value of combined use of Ga-68 DOTATATE and F-18 FDG PET/CT scan to better choose therapy. Surg Neurol Int 2017;8:162 doi:10.4103/sni.sni_498_16 pmid:28840066

   CrossRefPubMed
8. 8.↵
   2. John M,
   3. Meyerhof W,
   4. Richter D, et al

   . Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 1996;38:33–39 doi:10.1136/gut.38.1.33 pmid:8566856

   Abstract/FREE Full Text
9. 9.↵
   2. Krenning EP,
   3. Kwekkeboom DJ,
   4. Bakker WH, et al

   . Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–31 doi:10.1007/BF00181765 pmid:8404961

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Bombardieri E,
    3. Ambrosini V,
    4. Aktolun C, et al

    ; Oncology Committee of the EANM. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:1441–48 doi:10.1007/s00259-010-1473-6 pmid:20461371

    CrossRefPubMed
11. 11.↵
    2. Lamberts SW,
    3. Bakker WH,
    4. Reubi JC, et al

    . Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323:1246–49 doi:10.1056/NEJM199011013231805 pmid:2170840

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Johnbeck CB,
    3. Knigge U,
    4. Loft A, et al

    . Head-to-head comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: a prospective study of 59 patients with neuroendocrine tumors. J Nucl Med 2017;58:451–57 doi:10.2967/jnumed.116.180430 pmid:27660147

    Abstract/FREE Full Text
13. 13.↵
    2. Hope TA,
    3. Bergsland EK,
    4. Bozkurt MF, et al

    . Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med 2018;59:66–74 doi:10.2967/jnumed.117.202275 pmid:29025982

    FREE Full Text
14. 14.↵
    2. Hope TA

    . Updates to the appropriate-use criteria for somatostatin receptor PET. J Nucl Med 2020;61:1764 doi:10.2967/jnumed.120.257808 pmid:33262268

    FREE Full Text
15. 15.↵
    2. Hope TA,
    3. Allen-Auerbach M,
    4. Bodei L, et al

    . SNMMI procedure standard/EANM practice guideline for SSTR-PET: imaging neuroendocrine tumors. J Nucl Med 2023;64:204–10 doi:10.2967/jnumed.122.264860 pmid:36725249

    FREE Full Text
16. 16.↵
    2. Horbinski C,
    3. Nabors LB,
    4. Portnow J, et al

    . NCCN Guidelines Insights: Central Nervous System Cancers, Version 2.2022. Natl Compr Canc Netw 2023;21:12–20 doi:10.6004/jnccn.2023.0002 pmid:36634606

    CrossRefPubMed
17. 17.↵
    2. Nabors LB,
    3. Portnow J,
    4. Ahluwalia M, et al

    . Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020;18:1537–70 doi:10.6004/jnccn.2020.0052 pmid:33152694

    CrossRefPubMed
18. 18.↵
    2. Haddad RI,
    3. Bischoff L,
    4. Ball D, et al

    . Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20:925–51 doi:10.6004/jnccn.2022.0040 pmid:35948029

    CrossRefPubMed
19. 19.↵
    2. Catana C

    . Principles of simultaneous PET/MR imaging. Magn Reson Imaging Clin N Am 2017;25:231–43 doi:10.1016/j.mric.2017.01.002 pmid:28390525

    CrossRefPubMed
20. 20.↵
    2. Mayerhoefer ME,
    3. Prosch H,
    4. Beer L, et al

    . PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations. Eur J Nucl Med Mol Imaging 2020;47:51–60 doi:10.1007/s00259-019-04452-y pmid:31410538

    CrossRefPubMed
21. 21.↵
    2. Rogers L,
    3. Barani I,
    4. Chamberlain M, et al

    . Meningiomas: knowledge base, treatment outcomes, and uncertainties: a RANO review. J Neurosurg 2015;122:4–23 doi:10.3171/2014.7.JNS131644 pmid:25343186

    CrossRefPubMed
22. 22.↵
    2. Yao JC,
    3. Hassan M,
    4. Phan A, et al

    . One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72 doi:10.1200/JCO.2007.15.4377 pmid:18565894

    Abstract/FREE Full Text
23. 23.↵
    2. Pimlott SL,
    3. Sutherland A

    . Molecular tracers for the PET and SPECT imaging of disease. Chem Soc Rev 2011;40:149–62 doi:10.1039/B922628C pmid:20818455

    CrossRefPubMed
24. 24.↵
    2. Trouillas J,
    3. Jaffrain-Rea ML,
    4. Vasiljevic A, et al

    . How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 2020;12:514 doi:10.3390/cancers12020514 pmid:32098443

    CrossRefPubMed
25. 25.↵
    2. Kim SH,
    3. Roytman M,
    4. Madera G, et al

    . Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [68Ga]-DOTATATE PET/MRI analysis in patients with meningioma. Sci Rep 2022;12:9256 doi:10.1038/s41598-022-13467-9 pmid:35661809

    CrossRefPubMed
26. 26.↵
    2. Nyuyki F,
    3. Plotkin M,
    4. Graf R, et al

    . Potential impact of 68Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas. Eur J Nucl Med Mol Imaging 2010;37:310–18 doi:10.1007/s00259-009-1270-2 pmid:19763565

    CrossRefPubMed
27. 27.↵
    2. Prasad RN,
    3. Perlow HK,
    4. Bovi J, et al

    . ⁶⁸Ga-DOTATATE PET: the future of meningioma treatment. Int J Radiat Oncol Biol Phys 2022;113:868–71 doi:10.1016/j.ijrobp.2022.04.041 pmid:35772444

    CrossRefPubMed
28. 28.↵
    2. Mahase SS,
    3. Roth O'Brien DA,
    4. No D, et al

    . [⁶⁸Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol Adv 2021;3:vdab012 doi:10.1093/noajnl/vdab012 pmid:33738446

    CrossRefPubMed
29. 29.↵
    2. Hintz EB,
    3. Park DJ,
    4. Ma D, et al

    . Using 68Ga-DOTATATE PET for postoperative radiosurgery and radiotherapy planning in patients with meningioma: a case series. Neurosurgery 2023;93:95–101 doi:10.1227/neu.0000000000002377 pmid:32098443

    CrossRefPubMed
30. 30.↵
    2. Roytman M,
    3. Pisapia DJ,
    4. Liechty B, et al

    . Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications. Clin Imaging 2020;66:18–22 doi:10.1016/j.clinimag.2020.04.026 pmid:32442855

    CrossRefPubMed
31. 31.↵
    2. Shastry M,
    3. Kayani I,
    4. Wild D, et al

    . Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun 2010;31:1025–32 doi:10.1097/MNM.0b013e32833f635e pmid:20926978

    CrossRefPubMed
32. 32.↵
    2. Gimenez-Roqueplo AP,
    3. Caumont-Prim A,
    4. Houzard C, et al

    . Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL. EVA Investigators. J Clin Endocrinol Metab 2013;98:E162–73 doi:10.1210/jc.2012-2975 pmid:23162105

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Ikram A,
    3. Paraganglioma RA

    . StatPearls. StatPearls Publishing, 2022. https://www.ncbi.nlm.nih.gov/books/NBK549834/. Accessed May 22, 2023
34. 34.↵
    2. Zollinger LV,
    3. Wiggins RH,
    4. Cornelius RS, et al

    . Retropharyngeal lymph node metastasis from esthesioneuroblastoma: a review of the therapeutic and prognostic implications. AJNR Am J Neuroradiol 2008;29:1561–63 doi:10.3174/ajnr.A1114 pmid:18499797

    CrossRefPubMed
35. 35.↵
    2. Dublin AB,
    3. Bobinski M

    . Imaging characteristics of olfactory neuroblastoma (esthesioneuroblastoma). J Neurol Surg B Skull Base 2016;77:1–5 doi:10.1055/s-0035-1564053 pmid:26949582

    CrossRefPubMed
36. 36.↵
    2. Rostomily RC,
    3. Elias M,
    4. Deng M, et al

    . Clinical utility of somatostatin receptor scintigraphic imaging (octreoscan) in esthesioneuroblastoma: a case study and survey of somatostatin receptor subtype expression. Head Neck 2006;28:305–12 doi:10.1002/hed.20356 pmid:16470879

    CrossRefPubMed
37. 37.↵
    2. Even-Zohar N,
    3. Greenman Y

    . Management of NFAs: medical treatment. Pituitary 2018;21:168–75 doi:10.1007/s11102-018-0865-7 pmid:29344905

    CrossRefPubMed
38. 38.↵
    2. Fusco A,
    3. Giampietro A,
    4. Bianchi A, et al

    . Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 2012;15:571–78 doi:10.1007/s11102-011-0370-8 pmid:22207350

    CrossRefPubMed
39. 39.↵
    2. Gabalec F,
    3. Drastikova M,
    4. Cesak T, et al

    . Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas. Physiol Res 2015;64:369–77 doi:10.33549/physiolres.932821 pmid:25536318

    CrossRefPubMed
40. 40.↵
    2. Ramírez C,
    3. Cheng S,
    4. Vargas G, et al

    . Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 2012;97:1745–51 doi:10.1210/jc.2011-3163 pmid:22419713

    CrossRefPubMedWeb of Science
41. 41.↵
    2. Xiao J,
    3. Zhu Z,
    4. Zhong D, et al

    . Improvement in diagnosis of metastatic pituitary carcinoma by ⁶⁸Ga DOTATATE PET/CT. Clin Nucl Med 2015;40:129–31 doi:10.1097/RLU.0000000000000462 pmid:24873798

    CrossRefPubMed
42. 42.↵
    2. Novruzov F,
    3. Aliyev JA,
    4. Jaunmuktane Z, et al

    . The use of 68Ga DOTATATE PET/CT for diagnostic assessment and monitoring of 177Lu DOTATATE therapy in pituitary carcinoma. Clin Nucl Med 2015;40:47–49 doi:10.1097/RLU.0000000000000589 pmid:25275413

    CrossRefPubMed